AMPE Ampio Pharmaceuticals Inc.

0.39
+0.01  (+2%)
Previous Close 0.38
Open 0.39
Price To Book 4.88
Market Cap 55,461,066
Shares 142,207,862
Volume 290,772
Short Ratio 23.31
Av. Daily Volume 1,432,512

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

As of July 24, 2019 enrolment has reached approximately 30%.
Ampion
Osteoarthritis of the Knee
Phase 2b data released May 2015 did not meet endpoints
Optina
Diabetic Macula Edema

Latest News

  1. Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial
  2. Ampio Appoints Moss Adams LLP as the Company's New Independent Auditor
  3. Ampio Appoints Dan Stokely as the Company's new Chief Financial Officer
  4. Ampio Pharmaceuticals Announces Closing of $12 Million Public Offering
  5. Ampio Pharmaceuticals Announces Pricing of Public Offering
  6. Ampio Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
  7. Ampio Regulatory and Clinical Update
  8. Ampio Clinical, Regulatory and Corporate Update
  9. Ampio Pharmaceuticals Provides Regulatory Update
  10. Ampio Pharmaceuticals Provides Corporate Update
  11. Ampio Updates Regulatory Status for Ampion
  12. Research Report Identifies Wolverine World Wide, Viking Therapeutics, Ampio Pharmaceuticals, ArcelorMittal, Delphi Technologies, and Unit with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  13. Ampio Updates Status of Pivotal Clinical Trial of Ampion to be Carried Out Under a SPA
  14. Ampio Updates Regulatory and Publication status for Ampion™
  15. 3 Health Care Stocks Rallying After US Midterms
  16. Ampio Updates Regulatory and Clinical Status for Ampion™
  17. Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Ampio Pharmaceuticals, Inc. (AMPE) and Encourages AMPE Investors to Contact the Firm
  18. DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm